Involvement of Interleukin-1 in Immobilization Stress-induced Increase in Plasma Adrenocorticotropic Hormone and in Release of Hypothalamic Monoamines in the Rat
Overview
Affiliations
We investigated whether interleukin-1 (IL-1) activity in the rat hypothalamus was increased by immobilization stress (IS), and whether pretreatment with an interleukin-1 receptor antagonist (IL-1Ra) is capable of inhibiting IS-induced elevations of hypothalamic norepinephrine (NE), dopamine (DA), and serotonin (5-HT) and the levels of their metabolites as well as of plasma adrenocorticotropic hormone (ACTH). IL-1 activity was estimated with a bioassay using mouse thymocyte proliferation in the presence of concanavalin A. IL-1Ra was administered directly into the anterior hypothalamus, and monoamines were determined using a microdialysis technique and an HPLC system. First, we found that levels of IL-1 activity in the rat hypothalamus reached a maximum at 60 min after starting IS. Second, IL-1Ra (2 micrograms) significantly inhibited IS-induced increases in hypothalamic NE, DA, and 5-HT levels as well as the levels of their metabolites. In addition, IL-1Ra (2 micrograms) also inhibited the IS-induced elevation of plasma ACTH levels. Third, timing effects of IL-1Ra administration on the IS-induced monoamines or ACTH responses were examined. IL-1Ra (2 micrograms) administered at 5 or 60 min before the start of IS, but not at 5 or 60 min after IS had been started, exerted inhibitory effects on these responses, indicating that the effects of IL-1 occurred within 5 min after the initiation of IS. In summary, these results suggest that IS enhances biologically active IL-1 in the hypothalamus, and that hypothalamic IL-1 plays a role in the regulation of IS-induced responses including elevated monoamine release in the hypothalamus and activation of the hypothalamo-pituitary-adrenal axis. Moreover, since 5 min is too short a time for IS to induce production of IL-1, IS may augment the effects of preexisting IL-1 in the hypothalamus.
El-Sayed N, Khalil N, Saleh S, Aly R, Basta M J Mol Neurosci. 2024; 74(3):61.
PMID: 38954245 DOI: 10.1007/s12031-024-02232-4.
Hu D, Kabayama S, Watanabe Y, Cui Y Antioxidants (Basel). 2024; 13(3).
PMID: 38539846 PMC: 10967432. DOI: 10.3390/antiox13030313.
Connecting Dots between Mitochondrial Dysfunction and Depression.
Khan M, Baussan Y, Hebert-Chatelain E Biomolecules. 2023; 13(4).
PMID: 37189442 PMC: 10135685. DOI: 10.3390/biom13040695.
DeRosa H, Richter T, Wilkinson C, Hunter R Front Genet. 2022; 13:813510.
PMID: 35711940 PMC: 9196244. DOI: 10.3389/fgene.2022.813510.
Porter G, OConnor J Neurol Neurobiol (Tallinn). 2022; 4(3).
PMID: 35662811 PMC: 9164423. DOI: 10.31487/j.nnb.2021.03.03.